Yanxia Shi
- Oncology top 5%
- Cancer Treatment and Pharmacology 21
- HER2/EGFR in Cancer Research 18
- Lung Cancer Research Studies 6
- Cancer Research top 10%
- Breast Cancer Treatment Studies 12
-
- Advanced Breast Cancer Therapies 19
-
- Monoclonal and Polyclonal Antibodies Research 6
-
- Bladder and Urothelial Cancer Treatments 10
- Urinary and Genital Oncology Studies 6
- Journals
- Proceedings of the National Academy of Sciences (1 paper)Nature Communications (2 papers)Journal of Clinical Oncology (13 papers)
- Partner nations
- ChinaUnited StatesUnited Kingdom
In The Last Decade
Yanxia Shi
68 papers receiving 972 citations
Hit Papers
Peers
Comparison fields: 5 of 72
- Oncology 571
- Cancer Research 213
- Pulmonary and Respiratory Medicine 256
- Radiology, Nuclear Medicine and Imaging 141
- Molecular Biology 311
Countries citing papers authored by Yanxia Shi
This map shows the geographic impact of Yanxia Shi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yanxia Shi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yanxia Shi more than expected).
Fields of papers citing papers by Yanxia Shi
This network shows the impact of papers produced by Yanxia Shi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yanxia Shi. The network helps show where Yanxia Shi may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Yanxia Shi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2025 | 0 | |
| 3 | 2024 | 4 | |
| 4 | 2024 | 22 | |
| 5 | 2023 | 10 | |
| 6 | 2023 | 2 | |
| 7 | 2022 | 1 | |
| 8 | 2021 | 23 | |
| 9 | 2021 | 17 | |
| 10 | 2021 | 2 | |
| 11 | 2020 | 15 | |
| 12 | 2020 | 5 | |
| 13 | 2020 | 3 | |
| 14 | 2019 | 35 | |
| 15 | 2018 | 10 | |
| 16 | 2018 | 30 | |
| 17 | 2016 | 18 | |
| 18 | 2013 | 49 | |
| 19 | 2011 | 5 | |
| 20 | 2011 | 74 |
About Yanxia Shi
Yanxia Shi is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine, having authored 76 papers that have together received 982 indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (21 papers), Advanced Breast Cancer Therapies (19 papers), HER2/EGFR in Cancer Research (18 papers), Breast Cancer Treatment Studies (12 papers), Bladder and Urothelial Cancer Treatments (10 papers), Monoclonal and Polyclonal Antibodies Research (6 papers), Lung Cancer Research Studies (6 papers) and Urinary and Genital Oncology Studies (6 papers). The work is most often cited by research in Oncology (571 citations), Cancer Research (213 citations) and Pulmonary and Respiratory Medicine (256 citations). Yanxia Shi has collaborated with scholars based in China, United States and United Kingdom. Frequent co-authors include Zhongyu Yuan, Shusen Wang, Xin An, Roujun Peng, Tao Qin, Fei Xu, Cong Xue, Yuchen Cai, Qiufan Zheng and Wen Xia. Their work appears in journals such as Proceedings of the National Academy of Sciences, Nature Communications and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.